Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Related Citations for PubMed (Select 23901085)

1.

Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.

Zhu Z, Mathahs MM, Schmidt WN.

J Infect Dis. 2013 Nov 15;208(10):1653-63. doi: 10.1093/infdis/jit338. Epub 2013 Jul 29.

2.

Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?

Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, Bandyopadhyay S, McCaffrey AP, Schmidt WN.

Hepatology. 2010 Dec;52(6):1897-905. doi: 10.1002/hep.23921.

3.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

4.

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R.

Antiviral Res. 2010 Oct;88(1):95-106. doi: 10.1016/j.antiviral.2010.08.001. Epub 2010 Aug 10.

PMID:
20705106
5.

Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.

Johnson CL, Owen DM, Gale M Jr.

J Biol Chem. 2007 Apr 6;282(14):10792-803. Epub 2007 Feb 8.

6.

Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM.

Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41. doi: 10.1128/AAC.00699-08. Epub 2008 Sep 29.

7.

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.

Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, Pyles RB, Bourne N, Yi M, Li K, Lemon SM.

Gastroenterology. 2008 Nov;135(5):1710-1718.e2. doi: 10.1053/j.gastro.2008.07.023. Epub 2008 Jul 22.

PMID:
18725224
8.

Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.

Kaukinen P, Sillanpää M, Kotenko S, Lin R, Hiscott J, Melén K, Julkunen I.

Virol J. 2006 Sep 1;3:66.

9.

Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms.

Cheng G, Zhong J, Chisari FV.

Proc Natl Acad Sci U S A. 2006 May 30;103(22):8499-504. Epub 2006 May 17.

10.

Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.

Lee JC, Tseng CK, Young KC, Sun HY, Wang SW, Chen WC, Lin CK, Wu YH.

Br J Pharmacol. 2014 Jan;171(1):237-52. doi: 10.1111/bph.12440.

11.

Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction.

Chen WC, Wang SY, Chiu CC, Tseng CK, Lin CK, Wang HC, Lee JC.

Antimicrob Agents Chemother. 2013 Mar;57(3):1180-91. doi: 10.1128/AAC.02053-12. Epub 2012 Dec 17.

12.

High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.

Lee JC, Yu MC, Lien TW, Chang CF, Hsu JT.

Assay Drug Dev Technol. 2005 Aug;3(4):385-92.

PMID:
16180993
13.

Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.

Li XD, Sun L, Seth RB, Pineda G, Chen ZJ.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717-22. Epub 2005 Nov 21.

14.

Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon.

Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J, Meurs EF.

J Virol. 2005 Apr;79(7):3969-78.

15.

Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.

Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D.

J Viral Hepat. 2011 May;18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Epub 2011 Mar 23. Review.

PMID:
21470343
16.

DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication.

Kang X, Chen X, He Y, Guo D, Guo L, Zhong J, Shu HB.

Virology. 2013 Jan 20;435(2):385-94. doi: 10.1016/j.virol.2012.10.025. Epub 2012 Nov 5.

17.

Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.

Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.

J Viral Hepat. 2012 Feb;19(2):e81-8. doi: 10.1111/j.1365-2893.2011.01507.x. Epub 2011 Aug 16.

PMID:
22239530
18.

Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.

Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA.

J Virol. 2011 Jun;85(12):5961-9. doi: 10.1128/JVI.00308-11. Epub 2011 Apr 6.

19.

Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells.

Lee JC, Shih YF, Hsu SP, Chang TY, Chen LH, Hsu JT.

Anal Biochem. 2003 May 15;316(2):162-70.

PMID:
12711336
20.

A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.

Franco S, Clotet B, Martínez MA.

Virus Res. 2008 Feb;131(2):260-70. Epub 2007 Nov 26.

PMID:
18037183
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk